CARDIACSENSE Cardiacsense (about 5.67%) – Estimated deadlines for receiving CE and FDA approvals for the medical watch Post published:09/12/2020
TRAINPAIN TrainPain (approximately 5.69%) – The trial results of the treatment using the digital platform for people suffering from fibromyalgia syndrome in Belgium Post published:09/12/2020
CARDIACSENSE Cardiacsense (about 5.67%) began an experiment to prove the effectiveness of the smartwatch it developed in measuring continuous breathing rate Post published:26/11/2020
MERCHAVIA The Memorandum of Understanding does not require an investment of up to NIS 650,000 in Nervio against the allotment of shares Post published:26/11/2020
MERCHAVIA The memorandum of understanding does not require an investment of up to $ 350m in Okon Medical as part of a $ 1.5m round of funding Post published:27/10/2020
pdf1 Ora Smart (approximately 1.93%), has signed a distribution agreement for the sale of its products in China Post published:18/10/2020
CARDIACSENSE Cardiacsence (about 5.67%) – completed the first phase of an experiment to measure respiratory rate Post published:13/10/2020
JUVENTAS Astellas (about 0.6%) – announced the cancellation of the agreement with Juventas Post published:17/09/2020
CARDIACSENSE Cardiacsense (5.67%), has signed an exclusive distribution agreement for the sale of medical watches in the UAE Post published:14/09/2020
